The number of deals in the pharmaceutical space has the tendency to fluctuate, but in recent years there has been a proportional increase in the amount of strategic partnerships, acquisitions, and research collaborations struck in the oncology sector. Owing to increased competition between products and the growing trend for combination drug development, the oncology sector is particularly rich with strategic alliances and partnerships. Such collaborations are forged with the intention to maximize the market potential of current or emerging therapies.
The benefits of strategic collaborations include synergistic research and development capabilities, reduction in financial risk, and shortened drug development timelines. However, collaborative drug development efforts are not without their own challenges. Such deals and strategies are often struck to stay ahead of the competition, but the timelines for realization of the deal potential and their outcomes can differ considerably.
The arrival of the pharmaceutical patent cliff has also opened up a new market opportunity for copycat versions of blockbuster biologics in the style of biosimilar drug competition. However, the complexity of biologics development is a significant hindrance to market entry. The risks of development in this sector have also been a driving force in fostering greater commercial collaboration.
To better understand the current landscape, this executive briefing examines some of the deals and strategic practices commonly used in oncology and biosimilar development, important considerations for some recent deals, and what they mean for the companies involved.
Download the Art of the Oncology Deal Executive Briefing to better understand: